Syndax Pharmaceuticals (SNDX) Pipeline Is Strong Enough To Offset Entinostat Delay - Baird

March 8, 2019 6:24 AM

Baird analyst, Madhu Kumar, reiterated his Outperform rating on shares of Syndax Pharmaceuticals (NASDAQ: SNDX) after the company announced the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found